SPDR S&P Pharmaceuticals ETF (XPH)

  • Loading...
#4

Best Fit Health/Biotechnology Funds ETFs

U.S. News evaluated 29 Health/Biotechnology Funds ETFs and 14 make our Best Fit list. Our list highlights the best passively managed funds for long-term investors. Rankings are assigned based on comparisons with Best Fit funds in this category.

How we identify Best Fit Funds

Best Fit Scorecard
Costs Good
Tracking Error Excellent
Bid/Ask Ratio Good
Holdings Diversity Typical

Fund Description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.

Fund Snapshot Updated 07.29.2014

Previous Close $96.33 Expense Ratio 0.35%
YTD Return 9.77% Avg. 30-Day Volume 98,976
1-Year Return 30.5% Market Cap Loading...
Bid $96.27 Shares Outstanding 9,000,000
Ask $96.35 Dividends $0.54
Top 10 Holdings
Akorn Inc (AKRX) 4.25%
Salix Pharmaceuticals Inc (SLXP) 4.00%
Perrigo Co Plc (PRGO) 3.74%
Bristol Myers Squibb Co (BMY) 3.68%
Lilly Eli & Co (LLY) 3.63%
Pacira Pharmaceuticals Inc (PCRX) 3.62%
Allergan Inc (AGN) 3.59%
Questcor Pharmaceuticals Inc (QCOR) 3.51%
Actavis Plc (ACT) 3.51%
Zoetis Inc (ZTS) 3.50%
% of Total Holdings 37.00%

Sector Breakdown

Geographic Breakdown

Best Fit Health/Biotechnology Funds

See full rankings for Health/Biotechnology Funds

Quotes delayed at least 15 minutes. Market data provided by Interactive Data and powered by Interactive Data Managed Solutions. Fund data provided by Interactive Data and Morningstar. Contact U.S. News Best Funds. Use of this website constitutes acceptance of the Best Funds Terms and Conditions of Use.